Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
This is a phase 1/2 study of combined treatment with dupilumab (anti-IL-4Ra) and cemiplimab (anti-PD-1) in patients with early-stage, resectable non-small cell lung cancer (NSCLC). The study will include participants with a confirmed diagnosis of NSCLC who are deemed to...
Age: 18 years - 66+
Gender: All
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
This study is researching an investigational drug called fianlimab (also called REGN3767)
with two other medications called cemiplimab and chemotherapy, individually called a "study
drug" or collectively called "study drugs". 'Investigational' means that the study d...
Age: 18 years - 66+
Gender: All
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramuciruma...
Age: 18 years - 66+
Gender: All
Pembrolizumab for Advanced NSCLC and PS 2-3
This single center open-label trial will enroll a single cohort of patients with advanced
non-small cell lung cancer (NSCLC) who are ineligible for treatment with curative intent due
to 1) disease stage IV, or 2) inability to tolerate intensive surgery or chemo-radi...
Age: 18 years - 66+
Gender: All
A Study to Investigate the Safety, Tolerability, and Preliminary Anti-tumor Activity of Bemcentinib in Combination With Pembrolizumab Plus Pemetrexed and Carboplatin in Adult Participants With Untreated Non-squamous Non-small Cell Lung Cancer
The primary purpose of this study is to determine the safety and tolerability of the
combination of bemcentinib with chemo-immunotherapy (CIT) to identify the recommended phase 2
dose (RP2D) when administered as first line (1L) treatment in participants with locally...
Age: 18 years - 66+
Gender: All
Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/KEYVIBE-006)
This study is to evaluate the safety and efficacy of pembrolizumab/vibostolimab (MK-7684A) in
combination with concurrent chemoradiotherapy (cCRT) followed by pembrolizumab/vibostolimab
versus cCRT followed by durvalumab in participants with unresectable, locally ad...
Age: 18 years - 66+
Gender: All
Dupilumab_Metastatic NSCLC
This is an Phase Ib/2 study, single arm, single cohort study to determine the safety and
tolerability of Dupilumab with PD-(L)1 blockade for patients with relapsed/refractory
metastatic NSCLC. For Phase 2, to determine the effect of adding IL-4Ra blockade to PD-(L)1...
Age: 18 years - 66+
Gender: All
Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative
This phase II/III trial compares the addition of radiation therapy to the usual treatment
(immunotherapy with or without chemotherapy) versus (vs.) usual treatment alone in treating
patients with non-small cell lung cancer that may have spread from where it first st...
Age: 18 years - 66+
Gender: All
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety,
tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of
BLU-945, a selective EGFR inhibitor, as monotherapy or in combination with osimertinib...
Age: 18 years - 66+
Gender: All
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study
evaluating LN-145 in patients with metastatic non-small-cell lung cancer
Age: 18 - 70 years
Gender: All
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
This study is a Phase I/II, multicenter, first-in-human, open-label dose-escalation study of
BT8009 given as a single agent and in combination with pembrolizumab in participants with
advanced solid tumors associated with Nectin-4 expression or in participants with a...
Age: 18 years - 66+
Gender: All
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
This is a Phase 1/1b, open-label, first-in-human, dose-escalation and expansion study of
CHS-388, a monoclonal antibody that targets IL-27, as a monotherapy and in combination in
patients with solid tumors.
Age: 18 years - 66+
Gender: All
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer
This phase III trial studies how well atezolizumab added to the usual radiation therapy works
in treating patients with stage I-IIA non-small cell lung cancer. Immunotherapy with
monoclonal antibodies, such as atezolizumab, may help the body's immune system attack t...
Age: 18 years - 66+
Gender: All
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs.
osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of
the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR...
Age: 18 years - 66+
Gender: All
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
This screening and multi-sub-study randomized phase II/III trial will establish a method for
genomic screening of similar large cancer populations followed by assigning and accruing
simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of c...
Age: 18 years - 66+
Gender: All
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA
non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in
a patient's tumor cells may help doctors select the best treatment for patients that h...
Age: 18 years - 66+
Gender: All